natgillin/translations-raw huggingface dataset:
Although rapid, clearance for both men and women appears to decrease with age.
Kljub hitrosti je videti, da se očistek s starostjo pri moških in ženskah zmanjšuje.
The CHMP adopted the proposed revised wording:
CHMP je sprejel predlagano popravljeno besedilo:
The volume of the peripheral compartment was not sensitive to gender.
Volumen perifernega dela ni bil odvisen od spola.
Your doctor will discuss with you the potential risk of taking Gemzar during pregnancy.
Vaš zdravnik se bo pogovoril z vami glede možnega tveganja pri jemanju zdravila Gemzar med nosečnostjo.
No specific interaction studies have been performed (see section 5.2)
Specifičnih študij medsebojnega delovanja niso izvedli (glejte poglavje 5.2).
• not known: frequency can't be estimated from the available data
• ni znano: ocena pogostnosti iz danih podatkov ni možna
35396 Gießen
35396 Gießen Nemčija
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including vaccinations and medicines obtained without a prescription.
Obvestite svojega zdravnika ali bolnišničnega farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, vključno z vakcino, tudi če ste ga dobili brez recepta.
Urinary excretion: All.
Izločanje z urinom: Celotno.
This 4-week cycle is then repeated.
Ta 4-tedenski ciklus nato ponavljamo.
The pharmacokinetics of gemcitabine have been examined in 353 patients in seven studies.
Farmakokinetiko gemcitabina so raziskovali v sedmih študijah, pri 353 bolnikih.
The CHMP also deleted the mention of performance status and adopted the following wording:
CHMP je prav tako izbrisal omembo statusa učinkovitosti in sprejel naslednje besedilo:
The CHMP considers that the divergences identified at the start of the referral have been resolved and that all issues raised in the List of Questions and in the List of Outstanding Issues have been properly addressed and answered satisfactorily.
CHMP meni, da so bila razhajanja, opredeljena na začetku napotitvenega postopka, rešena in da so bila vsa vprašanja, ki so bila del seznama vprašanj in seznama posebej težavnih vprašanj, pravilno obdelana in zadovoljivo odgovorjena.
Tissue distribution: Extensive.
Porazdelitev v tkivih: Obsežna.
• you have, or have previously had liver disease, heart disease or vascular disease.
• imate ali ste imeli jetrno bolezen, srčno obolenje ali žilno bolezen.
Each pack contains 1 vial
Vsako pakiranje vsebuje 1 vialo.
These medicines kill dividing cells, including cancer cells.
Ta zdravila ubijajo celice, ki se delijo, vključno z rakavimi celicami.
Within a cycle
Med ciklusom
Gangrene of fingers or toes
Gangrena prstov na rokah in nogah
It is not known whether gemcitabine is excreted in human milk and adverse effects on the suckling child cannot be excluded.
Ni znano, ali se gemcitabin izloča v materino mleko in ni možno izključiti neželenih učinkov na dojenega otroka.
Frequencies are defined as: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1000 to <1/100), Rare (≥1/10,000 to <1/1000), Very Rare (<1/10,000).
Pogostnosti so določene kot: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko (< 1/10.000).
• Increased gamma-glutamyl transferase (GGT)
• Zvišana gama-glutamil transferaza (GGT)
The plasma protein binding was considered to be negligible.
Vezavo na plazemske beljakovine so ocenili kot zanemarljivo.
Frequencies of the observed side effects are defined as:
Pogostnosti opazovanih neželenih učinkov si definirane kot:
Based on results from animal studies and the mechanism of action of gemcitabine, this substance should not be used during pregnancy unless clearly necessary.
Na osnovi rezultatov iz študij na živalih in mehanizma delovanja gemcitabina, tega zdravila med nosečnostjo ne smete uporabljati, razen če je nujno potrebno.
If the preparation comes into contact with the eyes, this may cause serious irritation.
Če zdravilo pride v stik z očmi, lahko to povzroči resno draženje.
If the solution is spilled on the skin, rinse thoroughly with water.
Če se raztopina polije po koži, temeljito sperite z vodo.
You may want to seek counselling on sperm storage before starting your therapy.
Morda boste potrebovali nasvet glede shranjevanja semena pred začetkom vašega zdravljenja.
Reconstitution at concentrations greater than 40 mg/ml may result in incomplete dissolution and should be avoided.
Rekonstiticija pri koncentracijah, višjih od 40 mg/ml lahko vodi v nepopolno raztapljanje in se ji moramo izogibati.
For the recommended dosing schedule, gemcitabine elimination should be virtually complete within 5 to 11 hours of the start of the infusion.
Pri priporočeni shemi odmerjanja bi moralo biti izločanje gemcitabina praktično zaključeno v 5 do 11 urah po začetku infuzije.
Of these patients, approximately 45% had non-small cell lung cancer and 35% were diagnosed with pancreatic cancer.
Od teh bolnikov jih je približno 45 % imelo nedrobnocelični karcinom pljuč in 35 % karcinom trebušne slinavke.
The following table of undesirable effects and frequencies is based on data from clinical trials.
Naslednja preglednica neželenih učinkov in njihove pogostnosti je narejena na osnovi podatkov iz kliničnih preskušanj.
Reconstituted solution: The product should be used immediately.
Rekonstituirana raztopina: Zdravilo mora biti takoj uporabljeno.
• you have been vaccinated recently
• če ste nedavno prejeli vakcino.
This metabolite can be found in peripheral blood mononuclear cells and the information below refers to these cells.
Ta presnovek najdemo v enojedrnih celicah periferne krvi in spodnji podatki se nanašajo na te celice.
Critical Evaluation
Odločilno ovrednotenje
The proposed revisions to the Product Information were fully implemented.
Predlagani popravki navodila za uporabo so bili v celoti izvršeni.
Calculate the dose and the number of Gemzar vials needed.
Izračunajte odmerek ter število potrebnih vial.
Live vaccinations
Živa cepiva
Your doctor will use this body surface area to work out the right dose for you.
Vaš zdravnik bo to telesno površino uporabil za določitev za vas ustreznega odmerka.
Eli Lilly Norge AS, Postboks 6090 Etterstad, N-0601 Oslo Norway
Eli Lilly Norge AS, Postboks 6090 Etterstad, N-0601 Oslo Norveška
Vascular disorders Clinical signs of peripheral vasculitis and gangrene
Žilne bolezni Klinični znaki perifernega vaskulitisa in gangrene
Particular attention was given to the therapeutic indications of Gemzar.
Posebno pozornost so namenili terapevtskim indikacijam zdravila Gemzar.
You must tell your doctor as soon as possible when you start experiencing any of these side effects.
Obvestite svojega zdravnika kakor hitro je mogoče po tem, ko začnete imeti kateregakoli od teh neželenih učinkov.
Eli Lilly Ges.m.b.H Kölblgasse 8-10 1030 Wien Austria
Eli Lilly Ges.m.b.H Kölblgasse 8-10 1030 Wien Avstrija
However, myelosuppression is short lived and usually does not result in dose reduction and rarely in discontinuation.
Vendar je mielosupresija kratkoročna in običajno ne vpliva na znižanje odmerka ter redko na prekinitev.
Patients should be cautioned against driving or operating machinery until it is established that they do not become somnolent.
Bolnike je potrebno opozoriti naj ne vozijo in upravljajo s stroji, dokler ne ugotovijo, da ne postanejo zaspani.
1000 mg gemcitabine
1.000 mg gemcitabina
Grade 3 Grade 4 Grade 3 Grade 4
3. stopnja 4. stopnja 3. stopnja 4. stopnja
Liver problems: found through abnormal blood test results Blood in urine
Težave z jetri: ki se ugotovijo z nenormalnimi rezultati krvnih testov Kri v urinu
Gemzar is used in the treatment of the following types of cancer:
Zdravilo Gemzar se uporablja za zdravljenje naslednjih tipov raka:
Difficulty breathing
Težave z dihanjem
Concomitant radiotherapy (given together or ≤7 days apart): Toxicity has been reported (see section 4.5 for details and recommendations for use).
Sočasna radioterapija (dana skupaj ali ≤ 7 dni narazen): Poročali so o toksičnosti (glejte poglavje 4.5 za podrobnosti in priporočila za uporabo).
Trough concentration following once weekly dosing: 0.07-1.12 µg/ml, with no apparent accumulation.
Najnižja koncentracija po odmerjanju enkrat tedensko: 0,07-1,12 µg/ml, brez očitnega kopičenja.
If extravasation occurs, generally the infusion must be stopped immediately and started again in another blood vessel.
Če pride do ekstravazacije, moramo v splošnem infuzijo takoj prekiniti in jo ponovno začeti v drugi žili.
When gemcitabine is administered daily, high mortality among the animals but minimal antitumoural activity is observed.
Če gemcitabin dajemo dnevno, so opazili visoko smrtnost med živalmi, vendar minimalno protitumorsko aktivnost.
Dose modifications of gemcitabine within a cycle should be performed according to the following tables:
Spremembe odmerka gemcitabina med ciklusom morajo biti opravljene v skladu z naslednjimi preglednicami:
The CHMP requested clarifications on treatment continuation and more details specific to the individual indications, in particular breast cancer and ovarian cancer.
CHMP je zahteval pojasnila o nadaljevanju zdravljenja in več podrobnosti za posamezne indikacije, še posebej glede raka dojk in jajčnikov.
If, however, gemcitabine is given every third or fourth day, it can be administered in nonlethal doses with substantial antitumoural activity against a broad spectrum of mouse tumours.
Če pa gemcitabin dajemo vsak tretji ali četrti dan, ga lahko dajemo v neletalnih odmerkih z znatno protitumorsko aktivnostjo proti širokemu spektru mišjih tumorjev.
Half-life: This ranged from 42 to 94 minutes depending on age and gender.
Razpolovni čas: V razponu od 42 in 94 minut, odvisno od starosti in spola.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF GEMZAR
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA GEMZAR
Fatigue, which is not associated with anaemia, usually resolves after the first cycle.
Utrujenost, ki ni povezana z anemijo, se običajno izboljša po prvem ciklusu.
Peripheral blood counts may continue to deteriorate after gemcitabine administration has been stopped.
Periferne krvne vrednosti se lahko po prekinitvi dajanja gemcitabina še naprej slabšajo.
In vitro, the cytotoxic effect of gemcitabine is dependent on both concentration and time.
In vitro je citotoksični učinek gemcitabina odvisen tako od koncentracije kot od časa.
Monitoring for toxicity and dose modification due to toxicity
Spremljanje toksičnosti in sprememba odmerka glede na toksičnost
Paediatric population (< 18 years)
Otroci (< 18 let)
• Bronchospasm -usually mild and transient but may require parenteral treatment
• Bronhospazem - zlasti blag in prehoden, vendar bo morda potrebno peroralno zdravljenje
Subsequent cycles should consist of injections once weekly for 3 consecutive weeks out of every 4 weeks.
V naslednjih ciklusih dajemo injekcije enkrat tedensko v obdobju 3 zaporednih tednov na vsake 4 tedne.
If such effects develop, consideration should be made to discontinuing gemcitabine therapy.
Če pride do razvoja teh učinkov, je potrebno razmisliti o prekinitvi terapije z gemcitabinom.
Lilly, S.A., Avenida de la Industria, 30 28108 Alcobendas Madrid Spain
Lilly, S.A., Avenida de la Industria, 30 28108 Alcobendas Madrid Španija
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
V vsaki skupini pogostnosti so neželene reakcije navedene po padajoči resnosti.
Pre-clinical and clinical studies have shown that gemcitabine has radiosensitising activity.
Predklinične in kliničnih študije so pokazale, da ima gemcitabin radiosenzitizirajoče delovanje.
Do not drive a car or use machinery until you are sure that Gemzar treatment has not made you feel sleepy.
Ne vozite avtomobila in ne upravljajte z orodji ali stroji, dokler niste prepričani, da vam zdravljenje z zdravilom Gemzar ni povzročilo občutek zaspanosti.
However, the increase in these adverse reactions is not associated with an increased incidence of infections or haemorrhagic events.
Vendar povečanje neželenih učinkov ni povezano s zvišano incidenco vnetij in hemoragičnih dogodkov.
How frequently you receive your Gemzar infusion depends on the type of cancer that you are being treated for.
Kako pogosto boste prejemali infuzijo zdravila Gemzar je odvisno od tipa raka za katerega se zdravite.
Prolongation of the infusion time and increased dosing frequency have been shown to increase toxicity.
Pokazali so, da podaljšanje časa infudiranja in povečana pogostnost odmerjanja povečata toksičnost.
If no safety box is available, the equipment should be supplemented with a mask and protective glasses.
Če zaščitne komore ni na voljo, opremo nadomestite z masko in zaščitnimi očali.
• you develop breathing difficulties or feel very weak and are very pale (may be a sign of kidney failure).
• če se vam pojavijo težave z dihanjem ali se počutite šibki in ste zelo bledi (je lahko znak popuščanja ledvic).
Postmarketing experience (spontaneous reports) frequency not known (can't be estimated from the available data)
Izkušnje v obdobju trženja zdravila (spontana poročila) katerih pogostnost ni znana (ocena iz danih podatkov ni možna)
However, the combination of gemcitabine and cisplatin had a better toxicity profile than MVAC.
Vendar je imela kombinacija gemcitabina in cisplatina boljši toksikološki profil kot MVAC.
Therefore the CHMP considers that the proposed broad indication “bladder cancer” is not justified, as the data provided was not sufficient to support the indication in superficial bladder cancer.
Zato je CHMP mnenja, da predlagana, široko zastavljena indikacija "rak sečnega mehurja", ni utemeljena, ker predloženi podatki niso bili zadostni, da bi lahko podprli indikacijo površinskega raka sečnega mehurja.
Gemcitabine does not accumulate when administered once weekly.
Gemcitabin se pri dajanju enkrat tedensko ne kopiči.
PHADISCO LTD 185 Giannou Kranidioti Avenue CY-2234 Latsia Cyprus
PHADISCO LTD 185 Giannou Kranidioti Avenue CY-2234 Latsia Ciper
Dose modifications due to haematological toxicity in subsequent cycles, for all indications The gemcitabine dose should be reduced to 75% of the original cycle initiation dose, in the case of the following haematological toxicities:
Prilagoditve odmerka zaradi hematološke toksičnosti v nadaljnjih ciklusih, za vse indikacije Odmerek gemcitabina je potrebno znižati na 75 % začetnega odmerka prvotnega ciklusa v primeru naslednjih hematoloških toksičnosti:
In patients with impaired bone marrow function, the treatment should be started with caution.
Pri bolnikih z okvarjenim delovanjem kostnega mozga je potrebno zdravljenje začeti previdno.
FARMASERVE LILLY S.A.Cl 15 Km National Road Athens-Lamia Kifissia, 14564 Greece
FARMASERVE LILLY S.A.Cl 15 Km National Road Athens-Lamia Kifissia, 14564 Grčija
Percentage of standard dose of Gemzar (%)
Odstotek standardnega odmerka zdravila Gemzar (%)
Data suggest that gemcitabine can be started after the acute effects of radiation have resolved or at least one week after radiation.
Podatki kažejo, da lahko z gemcitabinom začnemo po tem, ko akutni učinki obsevanja izzvenijo ali najmanj en teden po obsevanju.
This dosage may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition.
Ta odmerek bo morda prilagojen ali bo zdravljenje preloženo, odvisno od števila vaših krvnih celic in vašega splošnega stanja.
During the week following administration, 92 to 98% of the dose of gemcitabine administered is recovered, 99% in the urine, mainly in the form of dFdU and 1% of the dose is excreted in faeces.
V tednu po dajanju gemcitabina se izloči 92 do 98 % odmerka gemcitabina, 99 % z urinom, zlasti v obliki dFdU in 1 % z blatom.
At gemcitabine plasma concentrations above 5 µg/ml, dFdCTP levels do not increase, suggesting that the formation is saturable in these cells.
Pri plazemskih koncentracijah gemcitabina nad 5 µg/ml, se raven dFdCTP ne zviša, kar kaže, da v teh celicah lahko pride do nasičenja.
The dose should be given on Days 1, 8 and 15 of each 28-day cycle in combination with cisplatin.
Odmerek dajemo 1., 8. in 15. dan vsakega 28-dnevnega ciklusa v kombinaciji s cisplatinom.
You should not be given Gemzar: - if you are allergic (hypersensitive) to gemcitabine or any of the other ingredients of Gemzar.
Ne uporabljajte zdravila Gemzar: - če ste alergični na (preobčutljivi za) gemcitabin ali katerokoli sestavino zdravila Gemzar.
This improvement in PFS and response rate is only associated with some additional, readily manageable toxicity, resulting in a favourable risk benefit profile.
To izboljšanje PFS in mere odziva je povezano z zelo majhno mero dodatne, obvladljive toksičnosti, kar ima za posledico ugoden profil tveganj in koristi.
After incorporation into DNA, gemcitabine appears to induce the programmed cell death process known as apoptosis.
Po vključitvi v DNK, gemcitabin sproži programiran proces celične smrti, znan kot apoptoza.
For Section 4.8, the CHMP requested the clarification of the presentation of the post-marketing spontaneous report and also proposed a list of revised terms to be used in all the tables of adverse event in combination use in this section.
CHMP je za poglavje 4.8 zahteval pojasnilo predstavitve spontanih poročil, dobljenih po izdaji na trg, in predlagal seznam popravljenih izrazov, ki naj se jih uporabi v tem poglavju v vseh tabelah neželenih učinkov za kombinacijsko uporabo.
Therefore the CHMP agreed with the proposal but asked the MAH to justify the proposed wording regarding 5-FU refractory patients.
Zaradi tega se je CHMP strinjal s predlogom, vendar je zaprosil imetnika dovoljenja za promet z zdravilom, naj utemelji predlagano besedilo glede neodzivnih bolnikov 5-FU.
Number (%) of Patients MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) arm (N=196)
Število (%) bolnikov Veja z MVAC (metotreksat, vinblastin, doksorubicin in cisplatin) (N=196)
Laboratory evaluation of renal and hepatic function (including virological tests) should be performed periodically.
Potrebna je redna laboratorijska ocena ledvičnega in jetrnega delovanja (vključno z virološkimi testi).
It is primarily active against cells in the S phase and is given in the management of solid tumours.
Zdravilo v prvi vrsti deluje proti celicam v fazi S in se ga daje pri zdravljenju trdnih tumorjev.
The primary metabolite, 2'-deoxy-2', 2'-difluorouridine (dFdU), is not active and is found in plasma and urine.
Primarni presnovek 2'-dezoksi-2', 2'-difluoruridin (dFdU) ni aktiven in ga najdemo v plazmi in urinu.
There is no known antidote for overdose of gemcitabine.
Ni znanega antidota za preveliko odmerjanje gemcitabina.
After this addition there is essentially a complete inhibition in further DNA synthesis (masked chain termination).
Po tem dodatku je pravzaprav popolnoma zavrta nadaljnja sinteza DNK (maskiran konec verige).
If you would like to father a child during the treatment or in the 6 months following treatment, seek advice from your doctor or pharmacist.
Če bi med zdravljenjem ali v 6 mesecih po zdravljenju želeli spočeti otroka, se posvetujte s svojim zdravnikom ali s farmacevtom.
Gemzar belongs to a group of medicines called “cytotoxics”.
Zdravilo Gemzar spada v skupino zdravil, imenovanih “citotoksična zdravila”.
Your height and weight are measured to work out the surface area of your body.
Izmerili vam bodo vašo višino in telesno maso za določitev površino vašega telesa.
Non-concurrent (given >7 days apart)- Analysis of the data does not indicate any enhanced toxicity when gemcitabine is administered more than 7 days before or after radiation, other than radiation recall.
Ne-sočasno (dana > 7 dni narazen) - Analiza podatkov ne kaže kakršnekoli okrepljene toksičnosti pri dajanju gemcitabina več kot 7 dni pred ali po obsevanju, razen povratne radiacije.
Irregular heart rate (arrhythmia) (frequency not known).
Nepravilen utrip srca (aritmija) (pogostnost ni znana).
Abnormal urine tests: protein in urine Flu like symptoms including fever Oedema (swelling of ankles, fingers, feet, face)
Nenormalni urinski testi: beljakovine v urinu Gripi podobni simptomi, vključno z vročino Edem (otečeni gležnji, prsti, noge, obraz)
Pharmacotherapeutic group: pyrimidine analogues ATC code: L01BC05
Farmakoterapevtska skupina: analogi pirimidinskih baz, oznaka ATC: L01BC05
Handling of the solution for infusion should be done in a safety box and protective coats and gloves should be used.
Z raztopino za infundiranje morate ravnati v zaščitni komori ter uporabljati zaščitne plašče in rokavice.
These intracellular metabolites have not been detected in plasma or urine.
Teh znotrajceličnih presnovkov v plazmi ali urinu niso zaznali.
Mild to moderate renal insufficiency (GFR from 30 ml/min to 80 ml/min) has no consistent, significant effect on gemcitabine pharmacokinetics.
Blaga do zmerna okvara ledvic (GFR od 30 ml/min do 80 ml/min) ni imela skladnega, značilnega učinka na farmakokinetiko gemcitabina.
You must contact your doctor immediately if you notice any of the following: Fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common).
Takoj se obrnite na svojega zdravnika, če opazite karkoli od naštetega: Vročina ali vnetje (pogosto): če imate temperaturo 38 ºC ali več, znojenje ali druge znake vnetja (ker imate morda manj belih krvnih celic kot bi morali, kar je zelo pogosto).
Its action is phase-specific such that gemcitabine primarily kills cells that are undergoing DNA synthesis (S-phase) and, under certain circumstances, blocks the progression of cells at the junction of the G1/S phase boundary.
Njegovo delovanje je fazno-specifično, tako da gemcitabin primarno ubija celice, ki so v fazi sinteze DNK (S-fazi) in, pod določenimi pogoji blokira razvoj celic v stiku med mejo G1/S faze.
The indication in pancreatic cancer is based on data from the pivotal Phase 3 study JHAY and the supporting study JHAZ.
Indikacija rak trebušne slinavke temelji na podatkih iz ključne študije III. faze JHAY in podporne študije JHAZ.
Severe skin reactions, including desquamation and bullous skin eruptions, Lyell's Syndrome, StevenJohnson Syndrome
Hude kožne reakcije, vključno z luščenjem in buloznimi kožnimi vzbrstmi, Lyellov sindrom, StevenJohnsonov sindrom
Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur.
Raztopine rekonstituiranega gemcitabina ne smemo shranjevati v hladilniku, ker lahko pride do kristalizacije.
In both studies it was found that tolerability was similar in the two treatment arms.
V obeh vejah obeh študij so ugotovili, da je bilo prenašanje podobno.
WHAT GEMZAR IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO GEMZAR IN ZAKAJ GA UPORABLJAMO
In the event of suspected overdose, the patient should be monitored with appropriate blood counts and receive supportive therapy, as necessary.
V primeru suma na preveliko odmerjanje je potrebno spremljati bolnikovo krvno sliko in po potrebi dati ustrezno podporno terapijo.
Gemcitabine solutions are for single use only.
Raztopine gemcitabina so samo za enkratno uporabo.
No effect on the fertility of females has been detected.
Učinka na plodnost samic niso zaznali.
A hospital pharmacist or doctor will have dissolved the Gemzar powder before it is given to you.
Bolnišnični farmacevt ali zdravnik bo pred dajanjem prašek zdravila Gemzar raztopil.
Omit dose* *Treatment omitted will not be re-instated within a cycle.
Izpuščen odmerek* *Zdravljenje med ciklusom ne bo ponovno uvedeno.
Fever accompanied by low white blood cell count (febrile neutropaenia) Anorexia (poor appetite)
Vročina spremljana z nizkim številom belih krvnih celic (febrilna nevtropenija) Anoreksija (slab apetit)
Gemzar may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer.
Zdravilo Gemzar se lahko daje samostojno ali se v kombinaciji z drugimi zdravili proti raku, odvisno od tipa raka.
There is no evidence to suggest that dose adjustments, other than those already recommended for all patients, are necessary in the elderly (see section 5.2).
Ni dokazov, ki bi kazali, da so pri starejših potrebne dodatne prilagoditve odmerkov, poleg tistih, ki so priporočene za vse bolnike (glejte poglavje 5.2).